David Allsup

5.4k total citations
54 papers, 618 citations indexed

About

David Allsup is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, David Allsup has authored 54 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Genetics, 21 papers in Pathology and Forensic Medicine and 16 papers in Immunology. Recurrent topics in David Allsup's work include Chronic Lymphocytic Leukemia Research (37 papers), Lymphoma Diagnosis and Treatment (21 papers) and Immunodeficiency and Autoimmune Disorders (12 papers). David Allsup is often cited by papers focused on Chronic Lymphocytic Leukemia Research (37 papers), Lymphoma Diagnosis and Treatment (21 papers) and Immunodeficiency and Autoimmune Disorders (12 papers). David Allsup collaborates with scholars based in United Kingdom, Italy and United States. David Allsup's co-authors include John C. Cawley, James R Bailey, Michael R. Boarder, Lynn Cawkwell, Ke Lin, Joseph R. Slupsky, Aura S. Kamiguti, Mirko Zuzel, Elena Kashuba and Lena Serrander and has published in prestigious journals such as Chemical Society Reviews, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

David Allsup

46 papers receiving 614 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Allsup United Kingdom 14 237 185 173 150 141 54 618
Ian B. Nicoud United States 17 55 0.2× 204 1.1× 95 0.5× 57 0.4× 31 0.2× 33 628
Man Tang Netherlands 16 110 0.5× 144 0.8× 247 1.4× 58 0.4× 60 0.4× 40 936
Isabelle Dubus France 15 96 0.4× 290 1.6× 98 0.6× 36 0.2× 36 0.3× 30 844
Roberta Angioni Italy 14 98 0.4× 270 1.5× 227 1.3× 23 0.2× 30 0.2× 19 703
Elena Ossipova Sweden 13 56 0.2× 331 1.8× 250 1.4× 50 0.3× 67 0.5× 30 1.1k
Lucio Morabito Italy 14 105 0.4× 177 1.0× 183 1.1× 89 0.6× 16 0.1× 35 735
Hele Everaus Estonia 12 76 0.3× 177 1.0× 65 0.4× 84 0.6× 17 0.1× 36 586
Idalina Beirão Portugal 16 56 0.2× 436 2.4× 60 0.3× 29 0.2× 179 1.3× 58 868
Mary Beth Tombes United States 15 39 0.2× 373 2.0× 97 0.6× 68 0.5× 26 0.2× 36 720

Countries citing papers authored by David Allsup

Since Specialization
Citations

This map shows the geographic impact of David Allsup's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Allsup with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Allsup more than expected).

Fields of papers citing papers by David Allsup

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Allsup. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Allsup. The network helps show where David Allsup may publish in the future.

Co-authorship network of co-authors of David Allsup

This figure shows the co-authorship network connecting the top 25 collaborators of David Allsup. A scholar is included among the top collaborators of David Allsup based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Allsup. David Allsup is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Gee, Melanie, et al.. (2025). How should abnormal uterine bleeding be managed in people with bleeding disorders: a systematic review of the literature and thematic synthesis. Research and Practice in Thrombosis and Haemostasis. 9(6). 103167–103167.
5.
James, Daniel S., et al.. (2024). High‐Risk Chronic Lymphocytic Leukemia Complicating the Course of Imatinib‐Treated Chronic Myeloid Leukemia: Successful Disease Management With Dual Tyrosine Kinase Inhibition. SHILAP Revista de lepidopterología. 2024(1). 1813512–1813512. 1 indexed citations
6.
Molica, S., David Allsup, & Diana Giannarelli. (2024). Prevalence of BTK and PLCG2 Mutations in BTK Inhibitor Treated CLL Patients Who Experience Disease Progression: A Meta-Analysis. Blood. 144(Supplement 1). 4630–4630. 1 indexed citations
7.
Price, Thomas W., Juan Gallo, Le Duc Tung, et al.. (2024). PEGylation of indium phosphide quantum dots prevents quantum dot mediated platelet activation. Journal of Materials Chemistry B. 13(3). 1052–1063. 3 indexed citations
8.
Taynton, Thomas, David Allsup, & Gavin Barlow. (2024). How can we optimize antifungal use and stewardship in the treatment of acute leukemia?. Expert Review of Hematology. 17(9). 581–593.
9.
Molica, Stefano, Constantine S. Tam, David Allsup, & Aaron Polliack. (2023). Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option. Cancers. 15(14). 3737–3737. 9 indexed citations
10.
Price, Thomas W., Jessica Lee, Nicole Hondow, et al.. (2023). Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets. Small. 20(12). e2304881–e2304881. 6 indexed citations
11.
Khan, Sujoy, et al.. (2023). An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies. Frontiers in Oncology. 13. 1135812–1135812. 8 indexed citations
12.
Pepper, Andrea, Antonella Zucchetto, Kevin Norris, et al.. (2021). Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. Leukemia. 36(1). 271–274. 4 indexed citations
13.
Caserta, Stefano, Sujoy Khan, Simon P. Hart, et al.. (2021). Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia. Frontiers in Immunology. 12. 766272–766272. 7 indexed citations
14.
Howard, Dena, Talha Munir, Lucy McParland, et al.. (2017). Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials. 18(1). 387–387. 25 indexed citations
15.
Till, Kathleen J., Jeffrey C. Allen, Ke Lin, et al.. (2017). Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. Scientific Reports. 7(1). 16784–16784. 13 indexed citations
16.
Howard, Dena, Talha Munir, Lucy McParland, et al.. (2017). Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL. Leukemia. 31(11). 2416–2425. 21 indexed citations
17.
18.
Allsup, David, et al.. (2010). Chronic lymphocytic leukaemia is a risk factor for venous thromboembolism. Leukemia Research. 35(3). 419–421. 21 indexed citations
19.
Kamiguti, Aura S., Lena Serrander, Ke Lin, et al.. (2005). Expression and Activity of NOX5 in the Circulating Malignant B Cells of Hairy Cell Leukemia. The Journal of Immunology. 175(12). 8424–8430. 99 indexed citations
20.
Allsup, David & John C. Cawley. (2004). Diagnosis, biology and treatment of hairy-cell leukaemia. Clinical and Experimental Medicine. 4(3). 132–138. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ian B. Nicoud Breakdown of academic impact, for papers by Man Tang Breakdown of academic impact, for papers by Isabelle Dubus Breakdown of academic impact, for papers by Roberta Angioni Breakdown of academic impact, for papers by Elena Ossipova Breakdown of academic impact, for papers by Lucio Morabito Breakdown of academic impact, for papers by Hele Everaus Breakdown of academic impact, for papers by Idalina Beirão Breakdown of academic impact, for papers by Mary Beth Tombes
Rankless by CCL
2026